Study of AT-752 in Patients With Dengue Infection

Key Inclusion Criteria: * 18-55 years of age at time of screening * Fever ≥38°C (or feeling feverish) with onset during the previous 48 hours * Live/work in or recent travel to dengue endemic area * Positive test confirming Dengue (DENV) on a NS1 antigen test or reverse transcription-polymerase chain reaction (RT-PCR) assay * Negative rapid diagnostic test result for Coronavirus (SARS-CoV-2) and Influenza A and B Key Exclusion Criteria: * Pregnant, plans to become pregnant within 90 days of screening, or breast feeding. * Has previously received any investigational or approved vaccine for dengue * Previous history of HIV, chronic hepatitis B infection, or current hepatitis C infection (from medical history) * Use of any antiviral drug within 30 days or within 5 half-lives of the active drug or metabolite (for long-acting antivirals) * Current use of anticoagulant or antiplatelet drugs or documented medical history of bleeding disorders * Current use of medications for treatment of inflammatory bowel disease or documented medical history of chronic gastrointestinal disease including inflammatory bowel disease * Immunocompromised due to use of immunosuppressive drugs including systemic corticosteroids (inhaled or topical corticosteroids are allowed) or any current disease or condition * Evidence of severe dengue disease * Confirmed or suspected Coronavirus (SARS-CoV-2) infection or contact with patients with confirmed SARS-CoV2 infection within 7 days prior to screening * Other clinically significant medical conditions or laboratory abnormalities, as described in the protocol.